Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, disorder of glycogen metabolism, glycogen storage disease II, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, lysosomal storage disease, metabolic disease, nervous system disorder, neuromuscular diseaseRecruitingPhase 1 / Phase 22026-07-20NCT07282847

2 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
AskBio Inc8
Bayer178

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Barrow Neurological InstitutePhoenixUnited States50
Duke UniversityDurhamUnited States91
Hospital of the University of PennsylvaniaPhiladelphiaUnited States142
NYU LangoneNew YorkUnited States34
Stanford Neuroscience Health CenterPalo AltoUnited States15
University of California, Irvine (UCI)IrvineUnited States1
University of Pittsburgh Medical Center (UPMC)PittsburghUnited States10
University of Texas Southwest Medical CenterDallasUnited States1
Virginia Commonwealth University (VCU)RichmondUnited States4